Smilemaker100

Membership Revoked
Removed
10+ Year Member
15+ Year Member
Feb 24, 2004
893
1
Visit site
Status
Manhattan-based Colgate-Palmolive Co. and biotech firm Introgen Therapeutics Inc. signed an agreement to develop oral care products aimed at fighting mouth cancer.

Colgate bought $20 million of Austin, Tex.-based Introgen’s shares and acquired the rights to any products developed by the two companies. Introgen uses gene therapy to create anti-cancer agents.

Researchers will use Introgen’s tumor suppressors to create oral rinses, gels and other products to treat patients diagnosed with leukoplakia -- a pre-cancerous condition that can lead to oral cancer.


http://www.medgadget.com/archives/2005/11/prevent_oral_ca_1.html
 

BigRedDentist

Senior Member
10+ Year Member
5+ Year Member
Dec 8, 2005
168
4
Status
Pre-Dental
Smilemaker100 said:
Manhattan-based Colgate-Palmolive Co. and biotech firm Introgen Therapeutics Inc. signed an agreement to develop oral care products aimed at fighting mouth cancer.

Colgate bought $20 million of Austin, Tex.-based Introgen’s shares and acquired the rights to any products developed by the two companies. Introgen uses gene therapy to create anti-cancer agents.

Researchers will use Introgen’s tumor suppressors to create oral rinses, gels and other products to treat patients diagnosed with leukoplakia -- a pre-cancerous condition that can lead to oral cancer.


http://www.medgadget.com/archives/2005/11/prevent_oral_ca_1.html
Good stuff. I wonder if they are using an antagonist of the PML binding domain. Anyone know the molecular basis?
 
About the Ads